PsychedelicNewsBreaks

FridayMay 06, 2022 2:15 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study

Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other conditions,’ and the company’s joint homing peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, ‘enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic…

Continue Reading

ThursdayMay 05, 2022 2:55 pm

PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author…

Continue Reading

ThursdayMay 05, 2022 12:45 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Featured on Success Story Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its cofounder and CEO Matt Stang were spotlighted in a recent episode of The Success Story podcast. During the interview, Stang talked all things Delic, including a history of the company, his decision to pivot from a career in cannabis to psychedelics, and what he believes the future holds for the company. “When we created [Delic], it was really under the supposition that a tipping point was coming for psychedelics the way it had come for cannabis,” said Delic Holdings…

Continue Reading

ThursdayMay 05, 2022 12:34 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take place from May 27-29, 2022, in Toronto, Canada. “It is an honor to participate in this inaugural conference devoted to psychedelic-assisted therapy and to be part of the rigorous scientific work being done in the field,” said Doug Drysdale, chief executive officer of Cybin. “The…

Continue Reading

WednesdayMay 04, 2022 2:55 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Ketamine Wellness Centers Now Offer NAD+ Infusion Therapy

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its Ketamine Wellness Centers (“KWC”)  are now offering  NAD+ infusion therapy at six clinic locations. KWC is the largest ketamine therapy provider in the country to offer the therapy, which is administered intravenously or intramuscularly. According to the company, the treatment can boost natural energy stores and immunity, along with brain and DNA function as well as cell communication; the treatment can also facilitate the healing chronic conditions such as depression, PTSD and anxiety. The treatment will be available at…

Continue Reading

ThursdayApr 28, 2022 2:40 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005. Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005),” reads a recent article. “Cybin recently announced that it commenced a…

Continue Reading

ThursdayApr 28, 2022 11:28 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate in Upcoming Planet MicroCap Showcase

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be presenting at this year’s Planet MicroCap Showcase; the event is scheduled for May 3–5, 2022. During the showcase, Delic Holdings cofounder and CEO Matt Stang will be sharing an overview of the company, including details about business expectations and growth opportunities; his discussion, slated for May 4, will also include a look at the company’s strategic plans for the remainder of this year. The premier in-person microCap finance event, the Planet MicroCap Showcase is held in Las Vegas and…

Continue Reading

WednesdayApr 27, 2022 1:57 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Focusing on Largely Underserved Indications

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare…

Continue Reading

WednesdayApr 27, 2022 1:39 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) KWC Committed to Providing Clinically-Backed, Accessible, Affordable Treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction…

Continue Reading

FridayApr 22, 2022 10:47 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the KCSA Psychedelics Virtual Investor Conference. Drysdale’s presentation is slated to begin at 11:00 a.m. ET on Thursday, April 28, 2022, at the live, interactive online event designed to invite investors to ask the company questions in real-time. Interested parties should visit https://ibn.fm/2G8rh to register for the conference and access the webcast. The archived webcast will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/OYUat About Cybin…

Continue Reading